Literature DB >> 19430501

A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT.

H Liu1, Y-F Li, B-C Liu, J-H Ding, B-A Chen, W-L Xu, J Qian.   

Abstract

Acute kidney injury (AKI) is a common early complication in patients with hematopoietic SCT (HSCT). However, there are limited data about the incidence and risk factors of AKI in patients with nonmyeloablative HSCT. We conducted a multicenter, retrospective cohort study of 62 patients from three institutions who were treated with similar protocols for nonmyeloablative HSCT. AKI was classified according to the Acute Kidney Injury Network criteria. It was shown that 29% of the patients developed AKI in the first 100 days after nonmyeloablative HSCT. The risk factor at baseline for AKI was incomplete HLA-matched transplant (odds ratio (OR) 3.6; 95% confidence interval (CI) 1.1-13.0). Complications such as acute GVHD, veno-occlusive disease of liver and sepsis were also associated with the development of AKI (OR 12.1; 95% CI 2.4-62.4). AKI was significantly associated with mortality (OR=4.7; 95% CI 1.9-11.5). We concluded that AKI is a very common complication in patients with nonmyeloablative HSCT, which is associated with incomplete HLA-matched transplant and complications, and has an important impact on the patients' first year of survival.

Entities:  

Mesh:

Year:  2009        PMID: 19430501     DOI: 10.1038/bmt.2009.99

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

Review 1.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 2.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

3.  Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Authors:  S R Kanduri; W Cheungpasitporn; C Thongprayoon; T Bathini; K Kovvuru; V Garla; J Medaura; P Vaitla; K B Kashani
Journal:  QJM       Date:  2020-09-01

4.  Hemoglobinuria in the Early Poststem-Cell-Transplant Period: Risk Factors and Association with Outcomes.

Authors:  Panagiotis Kompotiatis; Sandhya Manohar; Hassan B Alkhateeb; William J Hogan; Karl A Nath; Nelson Leung
Journal:  Kidney360       Date:  2021-08-25

Review 5.  Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Authors:  Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-13       Impact factor: 8.237

Review 6.  Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review.

Authors:  Vinod Krishnappa; Mohit Gupta; Gurusidda Manu; Shivani Kwatra; Osei-Tutu Owusu; Rupesh Raina
Journal:  Int J Nephrol       Date:  2016-11-03

7.  Incidence, Risk Factors and Prognosis of Acute Kidney Injury Following Hematopoietic Stem Cell Transplant: A Pilot Study.

Authors:  Amani Anwar Khalil; Laiali T Khalil; Abdalla Awidi
Journal:  Int J Stem Cells       Date:  2019-03-30       Impact factor: 2.500

Review 8.  Mini-review of kidney disease following hematopoietic stem cell transplant
.

Authors:  Ramy Sedhom; Daniel Sedhom; Edgar Jaimes
Journal:  Clin Nephrol       Date:  2018-06       Impact factor: 0.975

9.  Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Matthew H Abramson; Victoria Gutgarts; Junting Zheng; Molly A Maloy; Josel D Ruiz; Michael Scordo; Edgar A Jaimes; Insara Jaffer Sathick
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-16       Impact factor: 10.614

Review 10.  Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation.

Authors:  Masahiro Miyata; Kazunobu Ichikawa; Eri Matsuki; Masafumi Watanabe; Daniel Peltier; Tomomi Toubai
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.